Daruka Mahadevan

Professor, Mays Cancer Center

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Daruka Mahadevan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

5413 Citations
36 h-Index
107 Article
19 Review article
3 Chapter
3 Comment/debate
More

Tp53 mutations as a driver of metastasis signaling in advanced cancer patients
Pandey, R., Johnson, N., Cooke, L., Johnson, B., Chen, Y., Pandey, M., Chandler, J. & Mahadevan, D., Feb 2 2021, In: Cancers. 13, 4, p. 1-21 21 p., 597.
Research output: Contribution to journal › Article › peer-review

Open Access
A comparative analysis of tumors and plasma circulating tumor DNA in 145 advanced cancer patients annotated by 3 core cellular processes
Larson, K., Kannaiyan, R., Pandey, R., Chen, Y., Babiker, H. M. & Mahadevan, D., Mar 2020, In: Cancers. 12, 3, 701.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., Rini, B. I., Kummar, S., Weise, A. M., Riese, M. J., Markman, B., Emens, L. A., Mahadevan, D., Luke, J. J., Laport, G., Brody, J. D. & 13 others, Hernandez-Aya, L., Bonomi, P., Goldman, J. W., Berim, L., Renouf, D. J., Goodwin, R. A., Munneke, B., Ho, P. Y., Hsieh, J., McCaffery, I., Kwei, L., Willingham, S. B. & Miller, R. A., Jan 2020, In: Cancer Discovery. 10, 1, p. 40-53 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
50 Scopus citations
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
The COVID-19 and Cancer Consortium, Dec 14 2020, In: Cancer Cell. 38, 6, p. 761-766 6 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics
Chandana, S. R., Babiker, H. M. & Mahadevan, D., 2020, In: Expert Opinion on Investigational Drugs. 29, 12, p. 1413-1429 17 p.
Research output: Contribution to journal › Review article › peer-review

APTOSE BIOSCIENCES : 2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies
Daruka Mahadevan
6/11/21
1 item of Media coverage
Press/Media: Press / Media
APTOSE BIOSCIENCES : 2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS
Daruka Mahadevan
6/11/21
1 item of Media coverage
Press/Media: Press / Media
University of Texas: Mays Cancer Center Receives Five-Year NCI-Designated Cancer Center Renewal
Patrick M Sung, Mark Bonnen, Daruka Mahadevan & Ruben Mesa
8/18/20
1 item of Media coverage
Press/Media: Press / Media
Cancer Drugs Cause Large Cells that Resist Treatment; Scientist Aims to Stop It
Daruka Mahadevan
6/1/20
1 item of Media coverage
Press/Media: Press / Media
Scientist explore potential drugs to prevent cell resistance in different types of cancer
Daruka Mahadevan
5/29/20
1 item of Media coverage
Press/Media: Press / Media